Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT03853109
Registration number
NCT03853109
Ethics application status
Date submitted
22/02/2019
Date registered
25/02/2019
Date last updated
9/02/2024
Titles & IDs
Public title
AMG 404 in Patients With Advanced Solid Tumors
Query!
Scientific title
A Phase 1 Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 404, a Programmed Death-1 (PD-1) Antibody, in Patients With Advanced Solid Tumors
Query!
Secondary ID [1]
0
0
2018-004268-80
Query!
Secondary ID [2]
0
0
20180143
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Advanced Solid Tumors
0
0
Query!
Condition category
Condition code
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - AMG 404
Experimental: Cohort 1 - Cohort 1
Experimental: Cohort 2 - Cohort 2
Experimental: Cohort 3 - Cohort 3
Experimental: Cohort 4 - Cohort 4
Experimental: Cohort 6 - Cohort 6
Experimental: Cohort 7 - Cohort 7
Experimental: Cohort 8 - Cohort 8
Experimental: Cohort 9 - Cohort 9
Treatment: Drugs: AMG 404
AMG 404 will be examined for safety, tolerability, PK, and PD of AMG 404 in subjects with advanced solid tumors.
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Subject incidence of Dose limiting toxicities (DLTs)
Query!
Assessment method [1]
0
0
Dose limiting toxicities (DLTs)
Query!
Timepoint [1]
0
0
28 Days
Query!
Primary outcome [2]
0
0
Subject incidence of treatment emergent adverse events
Query!
Assessment method [2]
0
0
Query!
Timepoint [2]
0
0
28 Days
Query!
Primary outcome [3]
0
0
Subject incidence of treatment related adverse events
Query!
Assessment method [3]
0
0
Query!
Timepoint [3]
0
0
28 Days
Query!
Primary outcome [4]
0
0
Subject incidence of changes in vital signs
Query!
Assessment method [4]
0
0
Query!
Timepoint [4]
0
0
28 Days
Query!
Primary outcome [5]
0
0
Subject incidence of clinical laboratory tests
Query!
Assessment method [5]
0
0
Query!
Timepoint [5]
0
0
28 Days
Query!
Secondary outcome [1]
0
0
Maximum observed concentration (Cmax) of AMG 404
Query!
Assessment method [1]
0
0
Pharmacokinetic (PK) analysis of AMG 404
Query!
Timepoint [1]
0
0
24 months
Query!
Secondary outcome [2]
0
0
Time of maximum observed concentration (Tmax) of AMG 404
Query!
Assessment method [2]
0
0
Pharmacokinetic (PK) analysis of AMG 404
Query!
Timepoint [2]
0
0
24 months
Query!
Secondary outcome [3]
0
0
Area under the serum concentration-time curve (AUC) of AMG 404
Query!
Assessment method [3]
0
0
Pharmacokinetic (PK) analysis of AMG 404
Query!
Timepoint [3]
0
0
24 months
Query!
Secondary outcome [4]
0
0
Subject incidence of anti-AMG 404 antibodies
Query!
Assessment method [4]
0
0
Assess immunogenicity
Query!
Timepoint [4]
0
0
24 months
Query!
Secondary outcome [5]
0
0
Objective tumor response
Query!
Assessment method [5]
0
0
Query!
Timepoint [5]
0
0
24 months
Query!
Secondary outcome [6]
0
0
Duration of overall response
Query!
Assessment method [6]
0
0
Query!
Timepoint [6]
0
0
24 months
Query!
Secondary outcome [7]
0
0
Progression-free survival
Query!
Assessment method [7]
0
0
Query!
Timepoint [7]
0
0
24 months
Query!
Secondary outcome [8]
0
0
Disease control rate (DCR)
Query!
Assessment method [8]
0
0
Query!
Timepoint [8]
0
0
24 months
Query!
Secondary outcome [9]
0
0
Duration of stable disease
Query!
Assessment method [9]
0
0
Query!
Timepoint [9]
0
0
48 months
Query!
Eligibility
Key inclusion criteria
- Subject has provided informed consent prior to initiation of any study specific
activities/procedures.
- Age greater than or equal to 18 years old at the time of signing informed consent.
- Life expectancy of greater than 3 months, in the opinion of the investigator
- Subject must have histologically or cytologically confirmed metastatic or locally
advanced solid tumors not amenable to curative treatment with surgery or radiation.
- Cohort 7: participant must have one of the following tumor types: melanoma, small cell
lung cancer, NSCLC (PD-L1 positive), head and neck squamous cell cancer (PD-L1
positive), urothelial (PD-L1 positive), gastric or GEJ adenocarcinoma (PD-L1
positive), esophageal (squamous, PD-L1 positive), cervical (PD-L1 positive),
hepatocellular carcinoma, merkel cell carcinoma, squamous cell carcinoma of the skin,
renal cell carcinoma (clear cell) subtypes of sarcoma (undifferentiated pleiomorphic /
malignant fibrous histiocytoma, poorly differentiated and/or dedifferentiated
liposarcoma, alveolar soft tissue sarcoma, angiosarcoma), thymic carcinoma,
nasopharyngeal carcinoma (EBV positive), mesothelioma
- Cohort 8: participant must be MSI-H or MMR-deficient
- Cohort 9: participant must have NSCLC, PD-L1 positive, TPS = 50%; not have EGFR or ALK
or ROS1 genomic tumor aberrations and may not have received prior systemic treatment
for the advanced disease (prior neoadjuvant, adjuvant, or concurrent chemoradiation is
allowed).
- At least 1 measurable as defined by modified RECIST 1.1 which has not undergone biopsy
within 3 months of the screening scan. This lesion cannot be biopsied at any time
during the study. Note: if there is only one lesion available for biopsy and
radiographic assessment, it may be permitted to be biopsied after discussion with
sponsor.
- Subjects with treated brain metastases are eligible provided they meet the following
criteria: Definitive therapy was completed at least 2 weeks prior to enrollment. No
evidence of radiographic CNS progression or CNS disease following definitive therapy
and by the time of study screening. Patients manifesting progression in lesions
previously treated with stereotactic radiosurgery may still be eligible if
pseudoprogression can be demonstrated by appropriate means and after discussion with
the medical monitor.
- Any CNS disease is asymptomatic, any neurologic symptoms due to CNS disease have
returned to baseline or are deemed irreversible, the patient is off steroids for at
least 7 days (physiologic doses of steroids are permitted), and the patient is off or
on stable doses of anti-epileptic drugs for malignant CNS disease.
- Eastern Cooperative Oncology Group (ECOG) Performance Status of less than or equal to
2.
- Hematologic function, as follows without growth factor support within 2 weeks prior to
study day 1: Absolute neutrophil count (ANC) greater than or equal to 1.0 x 10E9/L;
Platelet count greater than or equal to 75 x 10E9/L; Hemoglobin greater than or equal
to 9 g/dL (90 g/L).
- Adequate renal laboratory assessments, as follows: Estimated glomerular filtration
rate based on MDRD (Modification of Diet in Renal Disease) calculation . 60
ml/min/1.73 m^2 for Cohorts 1, 2, and 4 Estimated glomerular filtration rate based on
MDRD (Modification of Diet in Renal Disease) calculation >= 45 ml/min/1.73 m^2 for
Cohorts 3, 6, 7, 8 and 9.
- Hepatic function, as follows: Total bilirubin less than or equal to 1.5 x ULN or less
than or equal to 3 x ULN for subjects with liver metastasis; AST less than or equal to
3 x ULN or less than or equal to' 5 x ULN for subjects with liver metastasis; ALT less
than or equal to 3 x ULN or less than or equal to 5 x ULN for subjects with liver
metastasis; Alkaline phosphatase less than or equal to 2.5 x ULN or less than or equal
to 5 x ULN for subjects with liver metastasis (Note: elevated alkaline phosphatase is
acceptable if it is due to non-hepatic associated pathology [eg, bone disease]).
- Subjects enrolled to Cohorts 7-9 must submit tumor tissue sample. Fresh tumor biopsies
may be performed if subject has a readily accessible tumor lesion and who consent to
the biopsies. If fresh biopsies cannot be obtained, archival tumor samples are
acceptable. Prior to enrollment it is required to determine that there is enough tumor
tissue available to be sent to the central laboratory: Cohorts 7 and 9: Archival
tissue collected up to 12 months prior to screening date is permitted. Biopsies
collected between 12-18 months prior to screening are allowed upon discussion with the
medical monitor. Subjects with EBV associated nasopharyngeal carcinoma may submit
biopsy with EBV test results from within 36 months prior to screening; Cohort 8:
Archival tissue with MSI-high/dMMR test results collected up to 36 months prior to
screening is permitted.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
100
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- Disease Related. Primary brain tumor, untreated or symptomatic brain metastases and
leptomeningeal disease (exception: benign asymptomatic tumors are permitted).
- Other Medical Conditions. History of other malignancy within the past 2 years, with
the following exception[s]: Malignancy treated with curative intent and with no known
active disease present for greater than or equal to 2 years before enrollment and felt
to be at low risk for recurrence by the treating physician. Adequately treated
non-melanoma skin cancer or lentigo maligna without evidence of disease. Adequately
treated cervical carcinoma in situ without evidence of disease. Adequately treated
breast ductal carcinoma in situ without evidence of disease. Prostatic intraepithelial
neoplasia without evidence of prostate cancer. Adequately treated urothelial papillary
noninvasive carcinoma or carcinoma in situ. Other malignancies which do not require
systemic therapy, may be considered upon discussion with the medical monitor.
- History of solid organ transplantation.
- Major surgery within 28 days of study day 1.
- Prior/Concomitant Therapy: Prior treatment with anti-programmed death 1 (PD-1),
anti-PD-L1, CTLA-4 or other checkpoint inhibitor drugs
- Anti-tumor therapy (radiotherapy, chemotherapy, antibody therapy, molecular targeted
therapy, or investigational agent) within 21 days prior to study day 1. Note:
Palliative radiotherapy is permitted.
- Live vaccine therapy within 4 weeks prior to study drug administration.
- Current treatment or within 14 days of day 1 with immunosuppressive corticosteroid
defined as greater than 10 mg prednisone daily or equivalent. Corticosteroids with no
or minimal systemic effect (such as topical or inhalation) are permitted. Note:
Corticosteroids > 10 mg prednisone used for management of contrast allergy for study
scans is allowed.
- Prior/Concurrent Clinical Study Experience: Currently receiving treatment in another
investigational device or drug study, or less than 21 days prior to study day 1 since
ending treatment on another investigational device or drug study(ies).
- Diagnostic Assessments: Evidence of interstitial lung disease or active,
non-infectious pneumonitis.
- History of any immune-related colitis. Infectious colitis is allowed if evidence of
adequate treatment and clinical recovery exists and at least 3 months interval
observed since diagnosis of colitis.
- History of allergic reactions or acute hypersensitivity reaction to antibody
therapies.
- Positive/Non-negative test for Human Immunodeficiency Virus (HIV).
- Has known active Hepatitis B (eg, hepatitis B antigen [HBsAg] reactive) or Hepatitis C
(eg, HCV RNA [qualitative] is detected).
- Subject currently has an active infection requiring systemic therapy.
- Active or history of any autoimmune disease or immunodeficiencies. Subjects with Type
I diabetes, vitiligo, psoriasis, hypo- or hyper- thyroid disease not requiring
immunosuppressive treatment are permitted.
- Myocardial infarction within 6 months of study day 1, symptomatic congestive heart
failure (New York Heart Association greater than class II), unstable angina, or
cardiac arrhythmia requiring antiarrhythmic medication.
- Unresolved toxicities from prior anti-tumor therapy, defined as not having resolved to
Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 grade 1, or are
stable and well controlled with minimal, local, or non-invasive intervention AND there
is agreement to allow by both the investigator and the Amgen Medical Monitor.
- Other Exclusions: Males and females of reproductive potential who are unwilling to
practice highly effective methods of birth control while on study through 6 months
(females) and 8 months (males) after receiving the last dose of AMG 404.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Non-randomised trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Other
Query!
Other design features
Query!
Phase
Phase 1
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
5/03/2019
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
2/11/2023
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
171
Query!
Recruitment in Australia
Recruitment state(s)
NSW,SA
Query!
Recruitment hospital [1]
0
0
Chris OBrien Lifehouse - Camperdown
Query!
Recruitment hospital [2]
0
0
The Queen Elizabeth Hospital - Woodville South
Query!
Recruitment postcode(s) [1]
0
0
2050 - Camperdown
Query!
Recruitment postcode(s) [2]
0
0
5011 - Woodville South
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
California
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Colorado
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Kentucky
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
North Carolina
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Texas
Query!
Country [6]
0
0
Belgium
Query!
State/province [6]
0
0
Edegem
Query!
Country [7]
0
0
Brazil
Query!
State/province [7]
0
0
Bahia
Query!
Country [8]
0
0
Brazil
Query!
State/province [8]
0
0
Rio Grande Do Sul
Query!
Country [9]
0
0
Brazil
Query!
State/province [9]
0
0
São Paulo
Query!
Country [10]
0
0
Brazil
Query!
State/province [10]
0
0
Rio de Janeiro
Query!
Country [11]
0
0
Canada
Query!
State/province [11]
0
0
Alberta
Query!
Country [12]
0
0
Japan
Query!
State/province [12]
0
0
Chiba
Query!
Country [13]
0
0
Japan
Query!
State/province [13]
0
0
Ehime
Query!
Country [14]
0
0
Japan
Query!
State/province [14]
0
0
Wakayama
Query!
Country [15]
0
0
Korea, Republic of
Query!
State/province [15]
0
0
Seoul
Query!
Country [16]
0
0
Poland
Query!
State/province [16]
0
0
Gdansk
Query!
Country [17]
0
0
Poland
Query!
State/province [17]
0
0
Warszawa
Query!
Country [18]
0
0
Singapore
Query!
State/province [18]
0
0
Singapore
Query!
Country [19]
0
0
Spain
Query!
State/province [19]
0
0
Cataluña
Query!
Country [20]
0
0
Spain
Query!
State/province [20]
0
0
Madrid
Query!
Country [21]
0
0
Taiwan
Query!
State/province [21]
0
0
Taipei
Query!
Country [22]
0
0
Taiwan
Query!
State/province [22]
0
0
Taoyuan
Query!
Country [23]
0
0
Turkey
Query!
State/province [23]
0
0
Ankara
Query!
Country [24]
0
0
Turkey
Query!
State/province [24]
0
0
Istanbul
Query!
Country [25]
0
0
Turkey
Query!
State/province [25]
0
0
Izmir
Query!
Country [26]
0
0
United Kingdom
Query!
State/province [26]
0
0
London
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Amgen
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
To evaluate the safety and tolerability of AMG 404, a monoclonal antibody that binds to PD-1
and inhibits its engagement with ligands, in patients with advanced solid tumors.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT03853109
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
MD
Query!
Address
0
0
Amgen
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT03853109
Download to PDF